Page 11 - Exscientia News Today

In its continued efforts to use AI to discover potential new drug candidates, then predict whether those therapies will work in an individual patient, the U.K.-based Exscientia has found a hometown hero to lead the charge.

By Colin Kellaher Shares of Exscientia PLC rose sharply in premarket trading Friday after the pharmatech company inked a research collaboration and license agreement potentially worth billions... | January 8, 2022

Sanofi is among the many pharmaceutical giants venturing into artificial intelligence to improve accuracy and reduce time spent on research.

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Collaborative efforts aim to accelerate drug discovery and improve clinical

Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia's AI-based capabilities and personalised medicine platform from target identification

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines * ... | January 7, 2022

Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.

Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients

Citi, acting through Citibank N.A., has been appointed by Exscientia plc ("Exscientia"), an AI-driven pharmatech company committed to designing and developing the best possible drugs in the fastest and

Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the